Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Bristol Myers Squibb : Celebrity Whistleblower Attorney™ Mychal Wilson’s Whistleblower Journey Premieres July 13th Primetime 8/7c On CBS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/06/2018 | 11:51pm CEST

A thrilling look into the real-life David vs. Goliath story of Celebrity Whistleblower Attorney™ Mychal Wilson

LOS ANGELES, CALIFORNIA, UNITED STATES OF AMERICA, July 6, 2018 /EINPresswire.com/ -- The whistleblower journey of Mychal Wilson, Esq. will premiere primetime Friday, July 13th at 8/7c on CBS.

CBS’ “Whistleblower” is a docuseries that “takes a thrilling look into the real-life David vs. Goliath stories of heroic people who put everything on the line in order to expose illegal and often dangerous wrongdoing when major corporations rip off U.S. taxpayers.”

WHISTLEBLOWER takes a thrilling look into the real-life David vs. Goliath stories of heroic people who put everything on the line in order to expose illegal and often dangerous wrongdoing when major corporations rip off U.S. taxpayers. Hosted by attorney Alex Ferrer, a former judge and police officer, each hour introduces cases in which ordinary people step up to do the extraordinary by risking their careers, their families and even their lives to ensure others are not harmed or killed by unchecked, unethical corporate greed.

The premiere episode will feature the cases concerning pediatric dental chain Kool Smiles and Celebrity Whistleblower Attorney™ Mychal Wilson’s whistleblower journey against his former employer pharmaceutical giant Bristol-Myers Squibb.

"I would like to thank CBS, Emmy Award winner and Senior Executive Producer Susan Zirinsky (48 HOURS, 48 HOURS: NCIS), Executive Producers Alex Ferrer, Ted Eccles, Gail Zimmerman and Allen Alter, Producer Caroline Sommers, and Director of Photography Leigh Hubner for the opportunity tell my story," says Mychal Wilson, Esq.

WHISTLEBLOWER is produced by CBS News for CBS Television Studios.

Mychal Wilson, Esq. is now a successful relator and Qui Tam attorney who has assisted various Federal and State agencies in the recovery of over $580 million in American taxpayer's dollars, who recently launched his new 30 minute news series titled "The Whistleblower” with Mychal Wilson, Esq.

Attorney Wilson’s own show titled "The Whistleblower” is a weekly nonpartisan political news program which airs every Tuesday live at 10:00 pm Eastern and 7:00 pm Pacific, on Roku, Amazon Fire TV, and coming soon on Apple TV, DISH TV and on demand thereafter.

About Mychal Wilson:


Mychal Wilson is a Qui Tam attorney and Entertainment law attorney, who is also a former actor/producer (Sundance Film Festival and HBO, STARZ!), and top big pharma cardiovascular/diabetes pharmaceutical sales representative for Bristol-Myers Squibb.

Currently, Mychal Wilson serves as legal counsel on several sealed and high profile unsealed whistleblower cases such as the False Claims Act (FCA) matter of the misbranding spinal device case U.S. ex rel. Dan Abrams Company, LLC v. Medtronic, Case No. 2:15-cv-01212 (C.D. Cal.), and the intervened Texas Medicaid Fraud Prevention Act drug pricing case, State of Texas v. Lupin, Case No. D-1-GN-16-005758 (TX), and U.S. ex rel Alexander Volkhoff v. Janssen, et al, Case No. 2:16-cv-06987-RGK-RAO (C.D. Cal.) involving the illegal sales and marketing of some its opioid and other prescription drugs

Mychal has been a member of the SAG-AFTRA ("Screen Actors Guild") since 1993 and is a media personality who regularly serves as a legal analyst on numerous media outlets such as BBC, The Doctors TV Show, Newsmax TV, OANN, RT and 790 KABC Radio Dr. Drew Midday Live.

Mychal Wilson, Esq. is a member of the State Bar of California and admitted to practice law in the Eastern, Northern, Central and Southern United States District Courts of California, and the Supreme Court of the United States (SCOTUS).

Twitter: @mychalwilsonesq
www.mychalwilsonesq.com

CONTACT:
The Whisteblower Show Booking Inquiries: press@mychalwilsonesq.com 

Media Booking Inquiries: 212.246.6236, JayJones@AlwaysONPR.tv
  
SOURCE The Law Office of Mychal Wilson

Related Links
http://www.mychalwilsonesq.com

Mychal Wilson, Esq.
The Law Office of Mychal Wilson
(424) 252-4232
email us here

Dr. Wendy Walsh Discusses Sexual Harassment Allegations Regarding Former Fox Host Bill O’Reilly

Copyright 1995-2018 IPD Group, Inc. All Right Reserved. , source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
10/18BRISTOL MYERS SQUIBB : to Showcase Immunoscience Research and Biomarker-Guided T..
AQ
10/17BRISTOL MYERS SQUIBB : to Showcase Immunoscience Research and Biomarker-Guided T..
BU
10/17COMPUGEN : BMS and Compugen join forces on solid tumour clinical trials
AQ
10/15BRISTOL MYERS SQUIBB : Announces Phase 3 CheckMate -331 Study Does Not Meet Prim..
AQ
10/15BRISTOL MYERS SQUIBB : Opdivo misses survival endpoint in Phase III for SCLC
AQ
10/13BRISTOL MYERS SQUIBB : BMS invests $12m in cancer immunotherapy tie-up with Comp..
AQ
10/13COMPUGEN : BMS invests $12m in Israeli Compugen for tumor collaboration
AQ
10/12BRISTOL-MYERS SQUIBB : Announces Phase 3 CheckMate -331 Study Does Not Meet Prim..
BU
10/12BRISTOL MYERS SQUIBB : Myers embraces a possible checkpoint collaborator, snaggi..
AQ
10/12BRISTOL MYERS SQUIBB : and Compugen Announce Clinical Collaboration to Evaluate ..
AQ
More news
News from SeekingAlpha
10/18BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Regeneron's Results, BMY's Failure, Novar.. 
10/18Bristol-Myers Squibb under pressure on positive data for Keytruda + Inlyta in.. 
10/16Neon Therapeutics Is An Emerging Player In Personalized Immunotherapy With Ca.. 
10/16AVEO ONCOLOGY : A High Risk, High Reward Play 
10/1610 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targe.. 
Financials ($)
Sales 2018 22 382 M
EBIT 2018 5 840 M
Net income 2018 4 709 M
Finance 2018 529 M
Yield 2018 2,76%
P/E ratio 2018 20,79
P/E ratio 2019 17,08
EV / Sales 2018 4,27x
EV / Sales 2019 3,95x
Capitalization 96 118 M
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 61,6 $
Spread / Average Target 4,6%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-6.15%96 118
JOHNSON & JOHNSON-4.19%374 137
PFIZER20.87%261 274
NOVARTIS0.07%212 170
ROCHE HOLDING LTD.-4.56%205 499
MERCK AND COMPANY23.44%191 007